Study summary

Niraparib maintenance delayed relapse but did not extend overall survival

PRIMA final survival · Phase 3 · Published September 2024, Annals of Oncology

What was tested

Final overall survival of niraparib maintenance against placebo after first chemotherapy for advanced ovarian cancer.

What they found

Niraparib kept cancer from growing longer, but overall survival was similar to placebo.

What it means

Highlights the value of matching PARP inhibitors to BRCA and HRD status.

Ann Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.